Resistência Medicamentosa no Tratamento do HIV:  Uma Revisão Sistemática / Drug resistance in the treatment of HIV:  A Systematic Review

Nayana Freitas Vieira Ribeiro; Pedro Walisson Gomes Feitosa; Vitor Lucas Daves de Moraes Oliveira; Marcos Vinicios de Oliveira Bezerra; Isadélia Constâncio de Oliveira; Liz Marjorie Batista de Freitas Leite

doi:10.14295/idonline.v16i60.3475

Autores

Nayana Freitas Vieira Ribeiro Faculdade de Medicina de Juazeiro do Norte-Estacio de Sá
Pedro Walisson Gomes Feitosa Universidade Federal do Cariri
Vitor Lucas Daves de Moraes Oliveira
Marcos Vinicios de Oliveira Bezerra Universidade Federal do Cariri - UFCA
Isadélia Constâncio de Oliveira Universidade Federal do Cariri, UFCA
Liz Marjorie Batista de Freitas Leite Unifesp

DOI:

https://doi.org/10.14295/idonline.v16i60.3475

Resumo

Resumo: O objetivo do presente estudo foi investigar a relação o desenvolvimento da resistência medicamentosa para os pacientes acometidos por infecção por HIV e submetidos aos tratamentos farmacológicos. Metodologia: Realizamos uma revisão sistemática nos bancos de dados eletrônicos PubMed e Scopus, seguindo os itens de Diretrizes para Revisões Sistemáticas e Metanálises (PRISMA). Selecionamos artigos originais que estudaram o desenvolvimento da resistência medicamentosa no tratamento para pacientes acometidos de infecção por vírus da imunodeficiência adquirida (HIV). Resultados: Inicialmente foram identificados 818 trabalhos nas bases pesquisadas (105 do PubMed, 713 do Scopus). Após exclusão por título e resumo foram selecionados 58 artigos para análise em texto completo. Ao final, 20 artigos foram selecionados como relevantes para compor a síntese qualitativa do presente trabalho. Conclusão: O desenvolvimento da resistência medicamentosa deveu-se aos tratamentos farmacológicos clássicos, à profilaxia de pré-exposição, às novas classes de medicamentos, às mutações, ao tempo dos tratamentos, ao aumento de células CD4+ e aos fatores individuais.

Palavras-chave: Resistência medicamentosa. Tratamento do HIV. Tratamento farmacológico.

Abstract:The aim of the present study was to investigate the relationship between the development of drug resistance in patients with HIV infection and undergoing pharmacological treatments. Methodology: We performed a systematic review in the PubMed and Scopus electronic databases, following the items of the Guidelines for Systematic Reviews and Meta-analyses (PRISMA). We selected original articles that studied the development of drug resistance in the treatment of patients with acquired immunodeficiency virus (HIV) infection. Results: Initially, 818 works were identified in the searched databases (105 from PubMed, 713 from Scopus). After exclusion by title and abstract, 58 articles were selected for full-text analysis. In the end, 20 articles were selected as relevant to compose the qualitative synthesis of the present work. Conclusion: The development of drug resistance was due to classic pharmacological treatments, pre-exposure prophylaxis, new drug classes, mutations, treatment duration, increase in CD4+ cells and individual factors.

Keywords: Drug resistance. HIV treatment. Pharmacological treatment.

Downloads

Não há dados estatísticos.

Biografia do Autor

Nayana Freitas Vieira Ribeiro, Faculdade de Medicina de Juazeiro do Norte-Estacio de Sá

1 Médica pela Faculdade de Medicina de Juazeiro do Norte-Estacio de Sá. [email protected];

Pedro Walisson Gomes Feitosa, Universidade Federal do Cariri

2 Acadêmico de Medicina pela Universidade Federal do Cariri. E-mail: [email protected];

Vitor Lucas Daves de Moraes Oliveira

3 Fisioterapeuta pelo Centro universitário São Lucas [email protected]

Marcos Vinicios de Oliveira Bezerra, Universidade Federal do Cariri - UFCA

Acadêmico de Medicina

Isadélia Constâncio de Oliveira, Universidade Federal do Cariri, UFCA

5 Graduada em Medicina pela Universidade Federal do Cariri, UFCA, Brasil. Preceptora adjunta da Faculdade Integrada de Patos, FIP, Brasil. Médica da Saúde da Família e Comunidade. [email protected].

Liz Marjorie Batista de Freitas Leite, Unifesp

6 Médica pela FMJ ( Faculdade de Medicina de Juazeiro do Norte). Residência em Clínica Médica pelo Hospital Municipal Mario Gatti - Campinas SP . Residência de Gastroenterologia clínica no Hospital do Servidor Público Estadual – IAMSPE. Mestranda em Hepatologia na Escola Paulista de Medicina – Unifesp.

Referências

AVIHINGSANON, Anchalee et al. Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults. International Journal Of Infectious Diseases, [s.l.], v. 61, p.89-96, ago. 2017. Elsevier BV. http://dx.doi.org/10.1016/j.ijid.2017.06.009.

BOLTZ, Vf et al. Linked dual-class HIV resistance mutations are associated with treatment failure. Jci Insight, [s.l], v. 19, n. 4, n.p out. 2019.

CAMBOU, Mary C.; LANDOVITZ, Raphael J.. Novel Antiretroviral Agents. Current Hiv/aids Reports, [s.l.], v. 17, n. 2, p.118-124, 12 fev. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1007/s11904-020-00486-2.

CHOI, Ju-yeon et al. The prevalence of antiretroviral multidrug resistance in highly active antiretroviral therapy-treated patients with HIV/AIDS between 2004 and 2009 in South Korea. Journal Of Clinical Virology, [s.l.], p.154-160, fev. 2014.

DONG, Ke et al. Prevalence of HIV-1 Drug Resistance among Patients with Antiretroviral Therapy Failure in Sichuan, China, 2010-2016. The Tohoku Journal Of Experimental Medicine, Tohoku, v. 247, n. 1, p.1-12, 11 jan. 2019.

DZANSI, Gladys; TORNU, Eric; CHIPPS, Jeniffer. Promoters and inhibitors of treatment adherence among HIV/AIDS patients receiving antiretroviral therapy in Ghana: Narratives from an underserved population. Plos One, [s.l.], v. 15, n. 3, p.1-13, 6 mar. 2020. Public Library of Science (PLoS). http://dx.doi.org/10.1371/journal.pone.0230159.

ENDALAMAW, Aklilu et al. HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis. : meta-analysis. Bmc Public Health, [s.l.], v. 20, n.1, n.p, 20 jan. 2020. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12889-020-8160-8.

ERIKSEN, Jaran et al. Antiretroviral treatment for HIV infection: Swedish recommendations 2019. Infectious Diseases, [s.l], v. 52, n. 5, p. 295-329, 2020. : https://doi.org/10.1080/23744235.2019.1707867.

ERON, Joseph J. et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. Aids, [s.l.], v. 32, n. 11, p.1431-1442, jul. 2018. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1097/qad.0000000000001817.

FARROKHI, M et al. HIV drug resistance among naïve HIV-infected patients in Iran. Journal Of Research In Medical Sciences, [s.l], v. 24, n. 1, p. 1-4, 26 abr. 2019.

GUIMARÃES, Monick Lindenmeyer et al. Assessing the HIV-1 Epidemic in Brazilian Drug Users: A Molecular Epidemiology Approach. Plos One, [s.l.], p.1-17, 4 nov. 2015.

GUNTHARD, Hf et al. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel. Clinical Infectious Diseases, [s.l], v. 68, n. 2, p. 177-187, 7 jan. 2019.

HAGINS, D et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. Hiv Medicine, [s.l.], v. 19, n. 10, p.724-733, 12 ago. 2018. Wiley. http://dx.doi.org/10.1111/hiv.12664.

HAUSER, Andrea et al. Increasing proportions of HIV-1 non-B subtypes and of NNRTI resistance between 2013 and 2016 in Germany: Results from the national molecular surveillance of new HIVdiagnoses. Plos One, [s.l.], v. 13, n. 11, p.1-18, 8 nov. 2018.

HODDER, Sally et al. Brief Report. Jaids Journal Of Acquired Immune Deficiency Syndromes, [s.l.], v. 78, n. 2, p.209-213, jun. 2018. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1097/qai.0000000000001663.

HOSSEINIPOUR, Mina et al. Viral Suppression and HIV Drug Resistance at 6 Months Among Women in Malawi’s Option B+ Program: Results From the PURE Malawi Study. Journal Of Acquired Immune Deficiency Syndrome, [s.l.], v. 75, n. 2, p.149-155, 1 jun. 2017.

IBRAHIM, Yassin et al. Oor adherence to antiretroviral therapy and associated factors among people living with HIV in Omdurman City, Sudan. Malaysian Journal Of Public Health Medicine, [s.l.], v. 14, n. 1, p.90-101, abr. 2014.

LI, Jianjian et al. Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China. Virology Journal, [s.l.], v. 16, n. 1, p.1-10, 8 jan. 2019. Springer Science and Business Media LLC. http://dx.doi.org/10.1186/s12985-018-1112-6.

LODI, S et al. Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals. Journal Of Acquired Immune Deficiency Syndrome, [s.l], v. 82, n. 3, p. 314-320, 1 nov. 2019.

LUO, Xiao-lu et al. Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy. Journal Of Pharmacological Sciences, [s.l.], v. 139, n. 4, p.275-279, abr. 2019. Elsevier BV. http://dx.doi.org/10.1016/j.jphs.2018.11.016.

MACHNOWSKA, Patrycja et al. Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort. Plos One, [s.l.], v. 14, n. 1, p.1-19, 16 jan. 2019. Public Library of Science (PLoS). http://dx.doi.org/10.1371/journal.pone.0209605.

MARRAZZO, Jeanne M. et al. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. New England Journal Of Medicine, [s.l.], v. 372, n. 6, p.509-518, 5 fev. 2015. Massachusetts Medical Society. http://dx.doi.org/10.1056/nejmoa1402269.

RUSCONI, Stefano. The impact of adherence to HIV/AIDS antiretroviral therapy on the development of drug resistance. Future Virology, [s.l], v. 12, n. 5, p.239-241, maio 2017.

SABINO, Thiago E. et al. Adherence to antiretroviral treatment and quality of life among transgender women living with HIV/AIDS in São Paulo, Brazil. Aids Care, [s.l.], p. 1-8, 6 jan. 2020. Informa UK Limited. http://dx.doi.org/10.1080/09540121.2019.1710449.

STELLBRINK, Hans-jürgen et al. Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment. Aids, [s.l.], v. 30, n. 8, p.1229-1238, maio 2016. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1097/qad.0000000000001058.

SZUBERT, Alexander J. et al. Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial. Plos Medicine, [s.l.], v. 14, n. 11, p.1-19, 14 nov. 2017.

SZUBERT, Alexander J. et al. Virological response and resistance among HIV- infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial. Plos Medicine, [s.l.], v. 14, n. 11, p.1-19, 14 nov. 2017.

VU, GT et al. Global Research on Quality of Life of Patients with HIV/AIDS: Is It Socio-Culturally Addressed? (GAP RESEARCH). International Journal Of Environmental Research And Public Health, [s.l], v. 17, n.6, n.p, 23 mar. 2020.

WAAL, Reneé de et al. HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. Journal Of Virus Eradication, [s.l.], v. 4, n. 2, p.55-58, 15 nov. 2018.

WEIS, Julie F. et al. Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation. Aids, [s.l.], v. 30, n. 1, p.31-35, jan. 2016. Ovid Technologies (Wolters Kluwer Health). http://dx.doi.org/10.1097/qad.0000000000000915.

YU, Danwei et al. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial–approved membrane fusion inhibitor. Journal Of Biological Chemistry, [s.l.], v. 293, n. 33, p.12703-12718, 21 jun. 2018. American Society for Biochemistry & Molecular Biology (ASBMB). http://dx.doi.org/10.1074/jbc.ra118.003538.

ZHANG, Yinfeng et al. Antiretroviral drug use and HIV drug resistance among young women in rural South Africa: HPTN 068. Journal Of Acquired Immune Deficiency Syndrome, [s.l.], v. 79, n. 3, p.315-322, nov. 2018.